Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Miettinen, J. Lasota.
Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.
Virchows Arch, 438 (2001), pp. 1-12
[2.]
M. Miettinen, M. Majidi, J. Lasota.
Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review.
Eur J Cancer, 38 (2002), pp. S39-S51
[3.]
M. Miettinen, L.H. Sobin, J. Lasota.
Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with longterm follow-up.
Am J Surg Pathol, 29 (2005), pp. 52-68
[4.]
B.P. Rubin.
Gastrointestinal stromal tumours: an update.
Histopathology, 48 (2006), pp. 83-96
[5.]
D. Gasparotto, S. Rossi, I. Bearzi, C. Doglioni, A. Marzotto, J.L. Hornick, A. Grizzo, C. Sartor, A. Mandolesi, R. Sciot, M. Debiec-Rychter, A.P. Dei Tos, R. Maestro.
Multiple primary sporadic gastrointestinal stromal tumors in the adult: an underestimated entity.
Clin Cancer Res, 14 (2008), pp. 5715-5721
[6.]
M. Miettinen, J. Lasota.
Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.
Arch Pathol Lab Med, 130 (2006), pp. 1466-1478
[7.]
S.C. Lin, M.J. Huang, C.Y. Zeng, T.I. Wang, Z.L. Liu, R.K. Shiay.
Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors.
World J Gastroenterol, 9 (2003), pp. 2809-2812
[8.]
C.D. Fletcher, J.J. Berman, C. Corless, F. Gorstein, J. Lasota, B.J. Longley, M. Miettinen, T.J. O’Leary, H. Remotti, B.P. Rubin, B. Shmookler, L.H. Sobin, S.W. Weiss.
Diagnosis of gastrointestinal stromal tumors: A consensus approach.
Hum Pathol, 33 (2002), pp. 459-465
[9.]
B.P. Rubin, C.D. Blanke, G.D. Demetri, R.P. Dematteo, C.D. Fletcher, J.R. Goldblum, J. Lasota, A. Lazar, R.G. Maki, M. Miettinen, A. Noffsinger, M.K. Washington, T. Krausz, Cancer Committee. College of American Pathologists.
Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.
Arch Pathol Lab Med, 134 (2010), pp. 165-170
[10.]
AJCC Cancer Staging Manual, 7th,
[11.]
B. Nilsson, P. Bümming, J.M. Meis-Kindblom, A. Odén, A. Dortok, B. Gustavsson, et al.
Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.
Cancer, 103 (2005), pp. 821-829
[12.]
B. Liegl, B. Liegl, J.L. Hornick, C.L. Corless, C.D. Fletcher.
Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.
Am J Surg Pathol, 33 (2009), pp. 437-446
[13.]
M. Debiec-Rychter, B. Wasag, M. Stul, I. De Wever, A. Van Oosterom, A. Hagemeijer, et al.
Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
J Pathol, 202 (2004), pp. 430-438
[14.]
F. Medeiros, C.L. Corless, A. Duensing, J.L. Hornick, A.M. Oliveira, M.C. Heinrich, et al.
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
Am J Surg Pathol, 28 (2004), pp. 889-894
[15.]
J. Martín-Broto, A. Gutiérrez, X. García del Muro, J.A. López- Guerrero, J. Martínez-Trufero, L.M. De Sande, et al.
A Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.
Ann Oncol, 21 (2010), pp. 1552-1557
[16.]
H.E. Lee, M.A. Kim, H.S. Lee, W.H. Kim.
Characteristics of KITnegative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
J Clin Pathol., 61 (2008), pp. 722-729
[17.]
G. Rossi, R. Valli, F. Bertolini, A. Marchioni, A. Cavazza, C. Mucciarini, et al.
PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract.
Histopathology, 46 (2005), pp. 522-531
[18.]
S. Parkkila, J. Lasota, J.A. Fletcher, W.B. Ou, A.J. Kivelä, K. Nuorva, et al.
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors.
Mod Pathol, 23 (2010), pp. 743-750
[19.]
S. Hirota, K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, S. Ishiguro, et al.
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
Science, 279 (1998), pp. 577-580
[20.]
M.C. Heinrich, C.L. Corless, A. Duensing, L. McGreevey, C.J. Chen, N. Joseph, et al.
PDGFRA activating mutations in gastrointestinal stromal tumors.
Science, 299 (2003), pp. 708-710
[21.]
P. Reichardt, P.C.W. Hogendoorn, E. Tamborini, M. Loda, A. Gronchi, A. Poveda, et al.
Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.
Semin Oncol, 36 (2009), pp. 290-301
[22.]
J. Lasota, M. Miettinen.
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumors.
Histopathology, 53 (2008), pp. 245-266
[23.]
C.L. Corless, M.C. Heinrich.
Molecular pathobiology of gastrointestinal stromal sarcomas.
Annu Rev Pathol, 3 (2008), pp. 557-586
[24.]
Y. Ma, M.E. Cunningham, X. Wang, I. Ghosh, L. Regan, B.J. Longley.
Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region.
J Biol Chem, 274 (1999), pp. 13399-13402
[25.]
C.L. Corless, J.A. Fletcher, M.C. Heinrich.
Biology of gastrointestinal stromal tumors.
J Clin Oncol, 22 (2004), pp. 3813-3825
[26.]
B.P. Rubin, M.C. Heinrich, C.L. Corless.
Gastrointestinal stromal tumour.
Lancet, 369 (2007), pp. 1731-1741
[27.]
J. Martín, A. Poveda, A. Llombart-Bosch, R. Ramos, J.A. López-Guerrero, J. García del Muro, Spanish Group for Sarcoma Research, et al.
Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
J Clin Oncol, 23 (2005), pp. 6190-6198
[28.]
J. Lasota, A. Wozniak, M. Sarlomo-Rikala, J. Rys, R. Kordek, A. Nassar, L.H. Sobin, et al.
Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases.
Am J Pathol, 157 (2000), pp. 1091-1095
[29.]
C.R. Antonescu, G. Sommer, L. Sarran, S.J. Tschernyavsky, E. Riedel, J.M. Woodruff, et al.
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.
Clin Cancer Res, 9 (2003), pp. 3329-3337
[30.]
S. Sakurai, S. Oguni, M. Hironaka, M. Fukayama, S. Morinaga, K. Saito.
Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese.
Jpn J Cancer Res, 92 (2001), pp. 494-498
[31.]
M.L. Lux, B.P. Rubin, T.L. Biase, C.J. Chen, T. Maclure, G. Demetri, et al.
KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.
Am J Pathol, 156 (2000), pp. 791-795
[32.]
C.L. Corless, A. Schroeder, D. Griffith, A. Town, L. McGreevey, P. Harrell, et al.
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vivo sensitivity to imatinib.
J Clin Oncol, 23 (2005), pp. 5357-5364
[33.]
C. Tarn, L. Rink, E. Merkel, D. Flieder, H. Pathak, D. Koumbi, et al.
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
Proc Natl Acad Sci USA, 105 (2008), pp. 8387-8392
[34.]
A. Agaimy, L.M. Terracciano, S. Dirnhofer, L. Tornillo, A. Foerster, A. Hartmann, et al.
V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
J Clin Pathol, 62 (2009), pp. 613-616
[35.]
K. Pauls, S. Merkelbach-Bruse, D. Thal, R. Buttner, E. Wardelmann.
PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features.
Histopathology, 46 (2005), pp. 166-175
[36.]
S. Hirota, A. Ohashi, T. Nishida, K. Isozaki, K. Kinoshita, Shinomura, et al.
Gain-of-function mutations of plateletderived growth factor receptor α gene in gastrointestinal stromal tumors.
Gastroenterology, 125 (2003), pp. 660-667
[37.]
B. Wasag, M. Debiec-Rychter, P. Pauwels, M. Stul, H. Vranckx, A.V. Oosterom, et al.
Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site.
Mod Pathol, 17 (2004), pp. 889-894
[38.]
P.G. Casali, Y. Blay.
ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointesninal stromal tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
Ann Oncol, 21 (2010), pp. v98-v102
[39.]
J.A. Carney.
Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence.
Mayo Clin Proc, 74 (1999), pp. 543-552
[40.]
M.C. Heinrich, K. Owzar, C.L. Corless, D. Hollis, E.C. Borden, C.D. Fletcher, et al.
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
J Clin Oncol, 26 (2008), pp. 5360-5367
[41.]
M. Debiec-Rychter, R. Sciot, A. Le Cesne, M. Schlemmer, P. Hohenberger, A.T. Van Oosterom, EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group, et al.
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Eur J Cancer, 42 (2006), pp. 1093-1103
[42.]
C.D. Blanke, G.D. Demetri, M. Von Mehren, M.C. Heinrich, B. Eisenberg, J.A. Fletcher, et al.
Long-term results from a randomized phase II trial of standard-versus higherdose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors ex-pressing KIT.
J Clin Oncol, 26 (2008), pp. 620-625
[43.]
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST).
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
J Clin Oncol, 28 (2010), pp. 1247-1253
[44.]
M.C. Heinrich, R.G. Maki, C.L. Corless, C.R. Antonescu, A. Harlow, D. Griffith, et al.
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
J Clin Oncol, 26 (2008), pp. 5352-5359
[45.]
M.C. Heinrich, C.L. Corless, C.D. Blanke, G.D. Demetri, H. Joensuu, P.J. Roberts, et al.
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
J Clin Oncol, 24 (2006), pp. 4764-4774
[46.]
E. Wardelmann, S. Merkelbach-Bruse, K. Pauls, N. Thomas, H.U. Schildhaus, T. Heinicke, et al.
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Clin Cancer Res, 12 (2006), pp. 1743-1749
[47.]
B. Liegl, I. Kepten, C. Le, M. Zhu, G.D. Demetri, M.C. Heinrich, et al.
Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
J Pathol, 216 (2008), pp. 64-74
[48.]
E. Tamborini, L. Bonadiman, A. Greco, V. Albertini, T. Negri, A. Gronchi, et al.
A new mutation in the kit ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumour patient.
Gastroenterology, 127 (2004), pp. 294-299
[49.]
L.L. Chen, J.C. Trent, E.F. Wu, G.N. Fuller, L. Ramdas, W. Zhang, et al.
A missence mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
Cancer Res, 64 (2004), pp. 5913-5919
[50.]
J.A. Fletcher, C.L. Corless, S. Dimitrijevic, M. Von Mehren, H. Eisenberg, H. Joensuu, et al.
Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST).
Proc Am Soc Clin Oncol, 22 (2003), pp. 3275
[51.]
J.A. Fletcher, B.P. Rubin.
KIT mutations in GIST.
Curr Opin Genet Dev, 17 (2007), pp. 3-7
[52.]
M.C. Heinrich, R.G. Maki, C.L. Corless, C.R. Antonescu, J.A. Fletcher, C.D. Fletcher, et al.
Sunitinib (SU) response in imatinibresistant (IM-R) GIST correlates with KIT and PDGFRA mutation status.
J Clin Oncol, 24 (2006), pp. 9502
[53.]
C.R. Antonescu, P. Besmer, T. Guo, T. Guo, K. Arkun, G. Hom, et al.
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Clin Cancer Res, 11 (2005), pp. 4182-4190
[54.]
C.D. Fletcher, J.J. Berman, C. Corless, F. Gorstein, J. Lasota, B.J. Longley, et al.
Diagnosis of gastrointestinal stromal tumors: A consensus approach.
Hum Pathol, 33 (2002), pp. 459-465
[55.]
J. Martín, A. Poveda, A. Llombart-Bosch, R. Ramos, X. García del Muro, J. Martínez-Trufero, et al.
Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of gastrointestinal stromal tumors (GIST). A GEIS study. General Poster Session.
Proc Am Soc Clin Oncol, 22 (2004), pp. 9029
[56.]
M. Miettinen, H. Makhlouf, L.H. Sobin, J. Lasota.
Gastrointestinal stromal tumors of jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.
Am J Surg Pathol, 30 (2006), pp. 477-489
[57.]
M. Miettinen, J. Lasota.
Gastrointestinal stromal tumors: pathology and prognosis at different sites.
Semin Diagn Pathol, 23 (2006), pp. 70-83
[58.]
J.S. Gold, M. Gönen, A. Gutiérrez, J.M. Broto, X. García del Muro, T.C. Smyrk, et al.
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
Lancet Oncol, 10 (2009), pp. 1045-1052
[59.]
R.P. DeMatteo, J.J. Lewis, D. Leung, S.S. Mudan, J.M. Woodruff, M.F. Brennan.
Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival.
Ann Surg, 231 (2000), pp. 51-58
[60.]
S. Singer, B.P. Rubin, M.L. Lux, C.J. Chen, G.D. Demetri, C.D. Fletcher, et al.
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
J Clin Oncol, 20 (2002), pp. 3898-3905
[61.]
J.F. Emile, N. Théou, S. Tabone, A. Cortez, P. Terrier, M.T. Chaumette, et al.
Groupe d’Étude des GIST. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors.
Clin Gastroenterol Hepatol, 2 (2004), pp. 597-605
[62.]
T. Aparicio, V. Boige, J.C. Sabourin, P. Crenn, M. Ducreux, A. Le Cesne, et al.
Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours.
Eur J Surg Oncol, 30 (2004), pp. 1098-1103
[63.]
S.C. Lin, M.J. Huang, C.Y. Zeng, T.I. Wang, Z.L. Liu, R.K. Shiay.
Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors.
World J Gastroenterol, 9 (2003), pp. 2809-2812
[64.]
Y. Fujimoto, Y. Nakanishi, K. Yoshimura, T. Shimoda.
Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients.
Gastric Cancer, 6 (2003), pp. 39-48
[65.]
J.K. Trupiano, R.E. Stewart, C. Misick, H.D. Appelman, J.R. Goldblum.
Gastric stromal tumors: a clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors.
Am J Surg Pathol, 26 (2002), pp. 705-714
[66.]
S.I. Ernst, A.E. Hubbs, R.M. Przygodzki, T.S. Emory, L.H. Sobin, T.J. O’Leary.
KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors.
Lab Invest, 78 (1998), pp. 1633-1636
[67.]
M. Taniguchi, T. Nishida, S. Hirota, K. Isozaki, T. Ito, T. Nomura, et al.
Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.
Cancer Res, 59 (1999), pp. 4297-300.17
[68.]
Y.K. Kang, M.S. Choe, M.H. Ryu, H.M. Chang, J.S. Kim, J.H. Yook, et al.
Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors.
Clin Cancer Res, 10 (2004), pp. 3076-3081
[69.]
J. Lasota, M. Jasinski, M. Sarlomo-Rikala, M. Miettinen.
Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas.
Am J Pathol, 154 (1999), pp. 53-60
[70.]
C.L. Corless, L. McGreevey, A. Haley, A. Town, M.C. Heinrich.
KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.
Am J Pathol, 160 (2002), pp. 1567-1572
[71.]
E. Wardelmann, I. Losen, V. Hans, I. Neidt, N. Speidel, E. Bierhoff, et al.
Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors.
Int J Cancer, 106 (2003), pp. 887-895
[72.]
T.S. Emory, L.H. Sobin, L. Lukes, D.H. Lee, T.J. O’Leary.
Prognosis of gastrointestinal smooth muscle (stromal) tumors: dependence on anatomic site.
Am J Surg Pathol, 23 (1999), pp. 82-87
[73.]
J. Martin-Broto, A. Gutiérrez, X. García del Muro, J.A. López-Guerrero, J. Martínez-Trufero, L.M. De Sande, et al.
Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse free surival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.
Ann Oncol, 21 (2010), pp. 1552-1557
[74.]
S. Lau, K.F. Tam, C.K. Kam, C.Y. Lui, C.W. Siu, H.S. Lam, et al.
Imaging of gastrointestinal stromal tumor (GIST).
Clin Radiol, 59 (2004), pp. 487-498
[75.]
G. Demetri, R. Benjamin, C.D. Blanke, J.Y. Blay, P. Casali, H. Choi, et al.
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
J Natl Compr Canc Netw, 5 (2007), pp. S1-S29
[76.]
C.M. Lee, H.C. Chen, T.K. Leung, Y.Y. Chen.
Gastrointestinal stromal tumor: Computed tomographic features.
World J Gastroenterol, 10 (2004), pp. 2417-2418
[77.]
P.G. Casali, L. Jost, P. Reichardt, M. Schlemmer, J.Y. Blay, ESMO guidelines working Group.
Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol, 19 (2008), pp. ii35-ii38
[78.]
D. Bensimhon, P. Soyer, M. Boudiaf, Y. Fargeaudou, J. Nemeth, M. Pocard, et al.
Imaging of gastrointestinal stromal tumors.
J Radiol, 90 (2009), pp. 469-480
[79.]
A.D. Levy, H.E. Remotti, W.M. Thompson, L.H. Sobin, M. Miettinen.
Gastrointestinal stromal tumors: radiologic features with pathologic correlation.
Radiographics, 23 (2003), pp. 283-304
[80.]
S. Hasegawa, R.C. Semelka, T.C. Noone, J.T. Woosley, H.B. Marcos, P.J. Kenney, et al.
Gastric stromal sarcomas correlation of MR imaging and histopathologic findings in nine patients.
Radiology, 208 (1998), pp. 591-595
[81.]
P.G. Casali, E. Fumagalli, A. Messina, C. Spreafico, D. Comandini, A. Comandone, et al.
Tumor response to imatinib mesylate in advanced GIST.
Proc Am Soc Clin Oncol, 22 (2004), pp. 9028
[82.]
A. Gelibter, M. Milella, A. Ceribelli, M. Zeuli, V. Ferraresi, A. Vecchione, et al.
PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.
Anticancer Res, 24 (2004), pp. 3147-3151
[83.]
H. Choi, C. Charnsangavej, S.C. Faria, H.A. Macapinlac, M.A. Burgess, S.R. Patel, et al.
Correlation of computed tomography (CT) and positron emission tomography (PET) in patients with metastatic GIST treated a single institution with imatinib mesylate proposal of new CT response criteria.
J Clin Oncol, 25 (2007), pp. 1753-1799
[84.]
R.S. Benjamin, H. Choi, H.A. Macapinlac, M.A. Burgess, S.R. Patel, L.L. Chen, et al.
We should desist using RECIST, at least in GIST.
J Clin Oncol, 25 (2007), pp. 1760-1764
[85.]
C. Stroszczynski, D. Jost, P. Reichardt, P. Chmelik, G. Gaffke, A. Kretzschmar, et al.
Follow-up of gastro-intestinal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI.
Eur Radiol, 15 (2005), pp. 448-456
[86.]
M. Mabille, D. Vanel, M. Albiter, A. Le Cesne, S. Bonvalot, C. Le Péchoux, et al.
Follow-up of hepatic and peritoneal of gastrointestinal tumors (GIST) under imatinib therapy requires different criteria of radiological evaluation (size is not everythig!!!).
Eur J Radiol, 69 (2009), pp. 204-208
[87.]
H. Choi, C. Charnsangavej, S. De Castro Faria, E.P. Tamm, R.S. Benjamin, M.M. Johnson, et al.
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
AJR Am J Roentgenol, 183 (2004), pp. 1619-1628
[88.]
P.G. Casali, L. Jost, P. Reichardt, M. Schlemmer, J.Y. Blay, ESMO Guidelines Working Group.
Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol, 20 (2009), pp. 64-67
[89.]
S. Shankar, E. Van Sonnenberg, J. Desai, P.J. DiPiro, A. Van den Abbeele, G.D. Demetri.
Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
Radiology, 235 (2005), pp. 892-898
[90.]
P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, et al.
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of United States, National Cancer Institute of Canada.
J Natl Cancer Inst, 92 (2000), pp. 205-216
[91.]
A.D. Van den Abbeele.
The lessons of GIST-PET and PET/CT: a new paradigma for Imaging.
Oncologist, 13 (2008), pp. 8-13
[92.]
NCCN Clinical Practice Guidelines in OncologyTM. Soft Tissue Sarcoma. V2.2010. Disponible en: http://www.gistonline.it/Files/Doc/NCCN%20Soft%20Tissue%20Sarcoma%20v.2.2010.pdf.
[93.]
DeMatteo RP, Owzar K, Antonescu CR, Maki R, Demetri GD, McCarter M, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. 2008 Gastrointestinal Cancers Symposium. Abstract No 8. Disponible en: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=53&abstractID=10450.
[94.]
B. Nilsson, K. Sjölund, L.G. Kindblom, J.M. Meis-Kindblom, P. Bümming, O. Nilsson, et al.
Adjuvant imatinib treatment improves recurrence-free survival in patients with highrisk gastrointestinal stromal tumours (GIST).
Br J Cancer, 96 (2007), pp. 1656-1658
[95.]
R.P. DeMatteo, K.V. Ballman, C.R. Antonescu, R.G. Maki, P.W. Pisters, G.D. Demetri, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team, et al.
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo controlled trial.
Lancet, 373 (2009), pp. 1097-1104
[96.]
Blackstein ME, Corless CL, Ballman KV, Antonescu C, Blanke C, Demetri GD, et al. Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor (GIST): North American intergroup phase III trial ACOSOG Z9001. 2010 Gastrointestinal Cancers Symposium. Abstract No 6. Disponible en: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1948.
[97.]
A. Gronchi, I. Judson, T. Nishida, A. Poveda, J. Martin, P. Reichardt, et al.
Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS).
Eur J Cancer, 45 (2009), pp. 1103-1106
[98.]
P.G. Casali, J.Y. Blay.
ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol, 21 (2010), pp. v98-v102
[99.]
B.L. Eisenberg, J. Harris, C.D. Blanke, G.D. Demetri, M.C. Heinrich, J.C. Watson, et al.
Phase II Trial of neoadyuvant/adyuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GITS): early results of RTOG 0132/ACRIN 6665.
J Surg Oncol, 99 (2009), pp. 42-47
[100.]
Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, et al. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumor (GITS). 2009 ASCO Annual Meeting. Abstract No 10550. Disponible en: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33955.
[101.]
Cassier PA, Blesius AA, Perol D, Ray-Coquard I, Adenis A, Bui B, et al. Neoadjuvant imatinib in patients with locally advanced GITS in the prospective BFR 14 Trial. 2009 ASCO Annual Meeting. Abstract No 10551. Disponible en: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=35501.
[102.]
M. Debiec-Rychter, R. Sciot, A. LeCesne, M. Schlemmer, P. Hohenberger, A.T. Van Oosterom, EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group, et al.
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors.
Eur J Cancer, 42 (2006), pp. 1093-1103
[103.]
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST).
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
J Clin Oncol, 28 (2010), pp. 1247-1253
[104.]
Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. Ray-Coquard IL, Bin Bui N, Adenis A,Rios M Sr, Bertucci F, Chabaud S, et al. 2010 ASCO Annual Meeting. Abstract No 10032. Dsiponible en: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=49383.
[105.]
A. Le Cesne, I. Ray-Coquard, B.N. Bui, A. Adenis, M. Rios, F. Bertucci, French Sarcoma Group, et al.
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
Lancet Oncol, 11 (2010), pp. 942-949
[106.]
G.D. Demetri, Y. Wang, E. Wehrle, A. Racine, Z. Nikolova, C.D. Blanke, et al.
Imatinib plasma levels correlate with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors (GIST).
J Clin Oncol, 27 (2009), pp. 3141-3147
[107.]
J.Y. Blay, S. Bonvalo, O. Casali, H. Choi, M. Debiec-Richter, A.P. Dei Tos, GIST consensus meeting panelists, et al.
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.
Ann Oncol, 16 (2005), pp. 566-578
[108.]
G.D. Demetri, Y. Wang, E. Wehrle, A. Racine, Z. Nikolova, C.D. Blanke, et al.
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
J Clin Oncol, 27 (2009), pp. 3141-3147
[109.]
J.R. Zalcberg, J. Verweij, P.G. Casali, A. Le Cesne, P. Reichardt, J.Y. Blay, EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group, et al.
Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg.
Eur J Cancer, 41 (2005), pp. 1751-1757
[110.]
C.D. Blanke, C. Rankin, G.D. Demetri, C.W. Ryan, M. Von Mehren, R.S. Benjamin, et al.
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J Clin Oncol, 26 (2008), pp. 626-632
[111.]
M. Debiec-Rychter, R. Sciot, A. Le Cesne, M. Schlemmer, P. Hohenberger, A.T. Van Oosterom, EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group, et al.
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Eur J Cancer, 42 (2006), pp. 1093-1103
[112.]
D. Demetri, A.T. Van Oosterom, C.R. Garret, M.E. Blackstein, M.H. Shah, J. Verweij, et al.
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumours after failure of imatinib: a randomised controlled trial.
Lancet, 368 (2006), pp. 1329-1338
[113.]
S. George, J.Y. Blay, P.G. Casali, A. Le Cesne, P. Stephenson, S.E. Deprimo, et al.
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
Eur J Cancer, 45 (2009), pp. 1959-1968
[114.]
C.L. Scaife, K.K. Hunt, S.R. Patel, R.S. Benjamin, M.A. Burgess, L.L. Chen, et al.
Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?.
Am J Surg, 186 (2003), pp. 665-669
[115.]
A. Gronchi, M. Fiore, F. Miselli, M.S. Lagonigro, P. Coco, A. Messina, et al.
Surgery of residual disease following moleculartargeted therapy with imatinib mesylate in advance/metastatic GIST.
Ann Surg, 245 (2007), pp. 341-346
[116.]
S. Bonvalot, H. Eldweny, C.L. Péchoux, D. Vanel, P. Terrier, A. Cavalcanti, et al.
Impact of surgery on advanced astrointestinal-stromal tumors (GIST) in the imatinib era.
Ann Surg Oncol, 13 (2006), pp. 1596-1603
[117.]
C.P. Raut, M. Posner, J. Desai, J.A. Morgan, S. George, D. Zahrieh, et al.
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
J Clin Oncol, 24 (2006), pp. 2325-2331
[118.]
R.P. DeMatteo, R.G. Maki, S. Singer, M. Gonen, M.F. Brennan, C.R. Antonescu.
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor.
Ann Surg, 245 (2007), pp. 347-352
[119.]
R.H. Andtbacka, C.S. Ng, C.L. Scaife, J.N. Cormier, K.K. Hunt, P.W. Pisters, et al.
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Ann Surg Oncol, 14 (2007), pp. 14-24
[120.]
C.D. Blanke, C. Rankin, G.D. Demetri, C.W. Ryan, M. von Mehren, R.S. Benjamin, et al.
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J Clin Oncol, 26 (2008), pp. 626-632
[121.]
M. Van Glabbeke, J. Verweij, P.G. Casali, A. Le Cesne, P. Hohenberger, I. Ray-Coquard, et al.
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
J Clin Oncol, 23 (2005), pp. 5795-5804
[122.]
S.S. Mudan, K.C. Conlon, J.M. Woodruff, J.J. Lewis, M.F. Brennan.
Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection.
Cancer, 88 (2000), pp. 66-74
[123.]
C.P. Raut, M. Posner, J. Desai, J.A. Morgan, S. George, D. Zahrieh, et al.
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
J Clin Oncol, 24 (2006), pp. 2325-2331
[124.]
P. Hohenberger, C. Langer, S. Pistorius, I. Iesalnieks, E. Wardelmann, E. Reichardt, et al.
Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST).
J Clin Oncol, 24 (2006), pp. 9500
[125.]
P. Reichardt, J. Blay, H. Gelderblom, M. Schlemmer, G.D. Demetri, N. Bin Bui, et al.
Phase III trial of nilotinib in patients with advanced GIST: first results from ENEST G3.
J Clin Oncol, 28 (2010), pp. 15s
[126.]
Wiebe L, Kasza E, Maki RG, D’Adamo DR, Chow WA, Wade JL, et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SE)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. 2008 ASCO Annual Meeting. Abstract No 10502. Disponible en: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31026.
[127.]
J. Maurel, A.S. Martins, A. Poveda, J.A. López-Guerrero, R. Cubedo, A. Casado, et al.
Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
Cancer, 116 (2010), pp. 3692-3701
Copyright © 2011. Asociación Española de Cirujanos
